Overexpression of KMT9α is associated with poor outcome in cholangiocarcinoma patients.

ABSTRACT:

Purpose

The newly discovered histone methyltransferase KMT9 serves as an epigenetic regulator of carcinogenesis in various cancer entities. For the first time, we investigated the presence of KMT9α in cholangiocarcinoma, the association with histologic subtypes, and its impact on survival.

Methods

A tissue microarray cohort of all CCA patients who underwent surgical resection with curative intent between 08/2005 and 12/2021 at the University Hospital Frankfurt was immunohistochemically analyzed with the KMT9α antibody. For overall survival, Kaplan-Meier curves and Cox-regression analyses were performed.

Results

In total, 174 patients were suitable for IHC analysis. Of the patients, 35.1% (n = 61) overexpressed KMT9α. Kaplan-Meier curves revealed a median OS of 34.75 m

SUBMITTER: Kinzler MN 

PROVIDER: S-EPMC12069507 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature